Kali Therapeutics has entered into a licensing agreement with Sanofi for the development of a novel tri-specific T-cell engager, KT501, aimed at treating a broad range of B cell-mediated autoimmune diseases.
Under the terms of the agreement, Sanofi will gain exclusive worldwide rights to KT501, a next-generation antibody engineered using Kali Therapeutics’ proprietary discovery platform. The therapy is currently being evaluated in a first-in-human clinical study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with rheumatoid arthritis.
The deal includes upfront and near-term payments totaling $180 million for Kali Therapeutics, with the potential for additional milestone payments of up to $1.05 billion tied to development and commercialization achievements. Kali is also eligible to receive tiered royalties on future product sales, ranging from high-single to double-digit percentages.
KT501 represents a new class of tri-specific antibodies designed to target multiple pathways simultaneously. The therapy incorporates advanced protein engineering, including a proprietary CD3 masking technology, which is intended to enhance safety by reducing cytokine release while maintaining therapeutic potency. This approach aims to overcome a key challenge in immunotherapy—balancing efficacy with tolerability.
According to Weihao Xu, the collaboration underscores the potential of Kali’s platform to address complex autoimmune conditions. He emphasized that KT501 is designed to effectively deplete a wide range of B cell populations, which play a central role in many autoimmune diseases, while minimizing adverse immune reactions.
Autoimmune diseases such as rheumatoid arthritis affect millions of people worldwide and often require long-term management. While existing treatments can help control symptoms, there remains a significant need for therapies that provide deeper and more durable disease control with improved safety profiles.
Sanofi’s extensive expertise in immunology and global development capabilities are expected to accelerate the advancement of KT501 through clinical development and toward potential commercialization. The partnership reflects a broader trend in the pharmaceutical industry toward multi-targeted biologics and innovative immune-modulating therapies.
If successful, KT501 could represent a significant step forward in the treatment of autoimmune diseases, offering patients a more effective and safer therapeutic option while expanding the boundaries of next-generation biologics.